WEE1 inhibitors have been evaluated in combination with a PARP-i as in the EEFORT trial, a phase II, noncomparative study of oral adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. Here, PARP1 is linked to ovarian carcinoma.